-1, max 12); and the median interval between cycles was 14.81 months (6-15.75, min 6, max 120). The EAS included SLE with 23 (43.4%) cases, systemic sclerosis with 7 (13.2%) cases, Sjögren's syndrome with 6 (11.3%) cases, vasculitis with 5 (9.4%) cases, Still disease with 3 (5.7%) cases, autoinmune cytopenias with 3 (5.7%) cases, dermatomyositis with 2 (3.8%) cases, Behçet's disease with 2 (3.8%) cases, IgG4 disease with 1 (1.9%) case and sarcoidosis with 1 case (1.9%). A partial response was observed in 27 patients (50.9%) and complete in 20 patients (37.7%). There was no response in 6 of the 53 patients (11.3%). The response by disease groups is detailed in Table 1 Background: Systemic autoimmune diseases (SAD) have traditionally been treated with steroids and immunosuppressants, but not all patients respond to this strategy. Rituximab (RTX) has been used in several SAD with favorable efficacy and safety results; there are only reports of isolated clinical experiences of small series of patients. The description of this drug safety data in daily clinical practice may be relevant. Objectives: To describe the adverse events and the hospital admissions during the treatment of a series of patients with SAD with RTX. Methods: Demographic data, related to disease and treatment, response and safety variables were included. We use the EULAR definitions of partial response (improvement of at least 50% of the main manifestations) and complete response (disappearance of the manifestations), because of the heterogeneity of the SAD. Results: We included 53 patients, 90.6% were women; the mean age at diagnosis was 31.42±14.33 years; and the median duration of disease at the onset of RTX 1.99 (0-7.5) years. Patients received a median of 2 cycles (1-3; min -1, max 12); and the median interval between cycles was 14.81 months (6-15.75;min 6, max 120). The SAD were SLE with 23 cases (43.4%), systemic sclerosis with 7 cases (13.2%), Sjögren's syndrome with 6 cases (11.3%), vasculitis with 5 cases (9.4%), Still disease with 3 cases (5.7%), autoinmune cytopenias with 3 cases (5.7%), dermatomyositis with 2 cases (3.8%), Behçet's disease with 2 cases (3.8%), IgG4 disease with 1 case (1.9%) and sarcoidosis with 1 case (1.9%). A partial response was observed in 27 patients (50.9%) and complete in 20 patients (37.7%). There was no response in 6 of the 53 patients (11.3%). Adverse events were detected in 15 of the 53 patients (28.3%) and 20 were hospitalized (37.7%) during the treatment with RTX (Table 1) .
Infecctions (9) Disease activity (8) Others ( Three patients developed hypogammaglobulinemia, only one of them was associated with recurrent respiratory infections and even hospitalized in one occasion. Febrile neutropenia was detected in 2 patients, and one of them required admission. Three patients were diagnosed with pneumonia and admitted for supportive and antibiotic treatment. Three other patients suffered gastroenteritis requiring admission in one of them. In two cases, low respiratory infections were repeated requiring admission on 7 occasions. There was also recurrent otitis and a severe hypersensitivity reaction.
Conclusions:
The most frequent adverse event were the infectious, mainly respiratory tract infections followed by an infusion reaction. The most common indication was active disease associated with severe infection that contraindicated the use of immunosuppressants in 24 patients and in 11 patients refractory activity disease to conventional therapy. The most frequent indications in patients with SLE were: 6 thrombocytopenias, 5 lupus nephritis, 4 pulmonary hemorrhage and 3 neurolupus; of the group of inflammatory myopathy the indications were: 6 dysphagia, 5 respiratory insufficiency and 4 refractory myopathy. In patients with SSp and PAN the indication was peripheral neuropathy. The mean number of IVIG applications was 3.3 (range 1-15). Activity scales were decreased in all patients with IVIG: mean SLEDAI at baseline 15.6 and in the follow up 4.5; in inflammatory myopathies remission was reached in 86% of the cases. The steroid dose was significantly reduced in most patients in the follow up. Four patients had adverse effects associated with IGIV: 2 with tachycardia and hypertension, one with acute pulmonary edema and one with hemolytic anemia. Conclusions: In our experience, IGIV administration was effective in controlling the activity of the autoimmune rheumatic disease, mainly in patients with concomitant infection, and with a good safety profile. Discussion: IGIV was an effective alternative treatment in patients with contraindication of conventional treatment or in refractory disease, however it is a high cost treatment and should be used in well selected cases Background: Low 25-OH Vitamin D is associated with SLE. Both a randomized clinical trial and a longitudinal cohort study proved that supplementation reduced SLE disease activity. Objectives: We examined whether Vitamin D benefits in SLE are dependent on the organ system. Methods: Vitamin D and SLEDAI components were measured at each cohort visit starting in 2010 and 16,519 visits of 1,345 different patients were included. The patients were 92% female, 50% Caucasian, 41% African American. Organ-specific disease activity was defined as a set of binary variables based on SLEDAI. If the patient received any score for any component, then the patient was defined as having that type of activity. Interestingly, after adjustment for repeated measures and covariates, the relationship between vitamin D and immunologic disease activity totally disappeared. However, for skin activity, there was a significantly elevated risk among those in the very extreme levels of vitamin D. For Renal Disease Activity, there was a significantly higher rate of renal disease activity among those with low levels of vitamin D. In addition, there was a clear trend such that the higher the vitamin D, the lower the risk of renal disease activity. We then conducted a "within person" analysis. In this analysis, each person serves as his own control, and the question is: "When a person has a vitamin D level lower than his/her average, are they more likely to have renal disease activity". Note, this analysis implicitly adjusts for race, sex, and all variables (measured and unmeasured) that are invariant within a person. The results are shown in Table 2 . Background: The benefit of vitamin D on SLE global and renal activity have now been proven by both cohort studies and a clinical trial. The benefits on cardiovascular risk factors, however, are less well understood. Objectives: We present the first longitudinal study on hyperlipidemia. Methods: A within-person aanalysis addressed the question of whether a person tends to have higher cholesterol when her vitamin D is lower than her average vitamin D. To assess this, for each visit, we calculated the difference between the vitamin D level at that visit and the person's average of vitamin D. Differences in the range of vitamin D <50 ng/mL were distinguished from differences in the range above 50 ng/mL. Then we modelled the relationship between these differences in vitamin D and the difference between the person's cholesterol at each visit and the person's average cholesterol. Results: P-value 0-50 ng/mL -3.4 (-3.9, -2.9) <0.0001 -3.1 (-3.6, -2.6) <0.0001 50+ ng/mL -1.1 (-1.7, -0.5) 0.0003 -1.0 (-1.7, -0.4) 0.0016 
